STAT3 mutation

Diagnostic workup revealed T-cell large granular lymphocytic leukemia (T-LGLL), characterized by a clonal CD8+ T-cell population with STAT3 mutation. A rare morphological finding of myeloperoxidase-negative Auer rod-like inclusions in the leukemic lymphocytes was observed, a feature seldom reported in this T-cell malignancy.

The patient responded to ciclosporin therapy with gradual haematological improvement and became transfusion-independent within 6 months. This case highlights the importance of molecular profiling in T-LGLL presentations and expands the known mutational spectrum of STAT3 It also raises the possibility that non-SH2 (Src homology 2) domain STAT3 mutations may contribute to disease pathogenesis and influence treatment response in T-LGLL.

Cyclosporine A (CsA) functions as a calcineurin inhibitor that perturbs T cell activation via calcineurin-nuclear factor of activated T cells (CaN-NFAT) signaling inhibitors, establishing its central role in hematological therapeutics. The manuscript further elaborates on pharmacological synergies between CsA and novel targeted agents including eltrombopag, ruxolitinib, and immune checkpoint inhibitors, while evaluating its capacity to surmount chemotherapeutic resistance and function as a bridging modality to CAR-T cell infusion. Lastly, we propose tiered management protocols for dose-limiting toxicities (nephrotoxicity and hypertension) and highlight emerging research frontiers in nanoformulation and artificial intelligence-guided therapeutic drug monitoring.

Cy-JAK/STAT pathway mutations are uncommon in AML, but each mutation has distinct biologic and clinical characteristics. The worse survival observed in patients with JAK2-mutated AML largely appeared to be driven by the co-occurrence of high-risk characteristics. Blast-phase MPN was associated with a dismal prognosis.

Importantly, "Tr1 skewing" is evident in both mouse T cells expressing cancer-associated STAT3 variants and humans afflicted with T-cell malignancies. These studies advance current understanding of how cancer-associated mutations impact STAT3 function and reveal anti-inflammatory properties that may help transformed T cells persist, expand, and/or avoid eradication.

In this narrative review we introduce signalling via the JAK-STAT3 pathway, focusing on potential mechanisms contributing to immune deficiencies in the constellation of a STAT3 gain of function. Furthermore, through an emblematic clinical case on the efficacy of anti-JAK therapy in STAT3 enteropathy, we review different enteropathies which recognize alterations in the JAK-STAT pathway and discuss the role of JAK inhibitors in this setting.

Importantly, incubation of a TAT-tagged STAT3 (454-467) peptide but not its scrambled version resulted in a reduction in STAT3 Y705 phosphorylation by IL-6/EGF. Taken together, our data demonstrates that the STAT3 CE epitope interacts with CARP-1 and p21Rac1, harbors novel sequences that activate STAT3 and promotes its nuclear translocation by IL-6/EGF.

These data demonstrate a mechanistic link between autoimmunity to PAD4 and CTL-associated disease in RA.

These findings suggest that RCD subtypes may share underlying mechanisms driven by clonal evolution and JAK-STAT dysregulation. They also highlight the potential limitations of JAK inhibitor monotherapy and the importance of molecularly informed therapeutic strategies.

STAT3/STAT5 mutations are early, dominant, and potentially pathogenic events in plasma cell myeloma. Their association with adverse clinical features and inferior survival supports their routine assessment and potential therapeutic targeting.

Particularly among those with STAT3 mutations, the 'QGXG' motif in 15 AA sequences of TCRβ complementarity-determining regions 3 (CDR3) regions was specifically recognized. These findings suggest that a specific immunogenetic background defined by particular HLA alleles, the expansion of somewhat limited T-cell clones and STAT3-mutated T cells are involved in the pathogenesis of chronic acquired PRCA.